VentiRx and Celgene Team Up for Cancer Treatment Development
October 8, 2012
Share:
Seattle-based VentiRx has nabbed $35 million in cash from Celgene, and Celgene obtained an exclusive option to acquire the company if its clinical trials are positive. The funding will support the development of VTX-2337, a novel immunotherapy for the treatment of cancer. Prior to the agreement, VentiRx landed over $52 million in combined venture funding from investors including ARCH Venture Partners, Domain Associates, Frazier Healthcare and MedImmune Ventures.
